Tirzepatide, the medication marketed as Mounjaro (for diabetes) and Zepbound (for obesity) includes a warning that it may render birth control pills less effective
It points to differences in GLP-1 receptor sensitivity, metabolic rate, and gastrointestinal adaptation
Rho GTPase signaling at the synapse: implications for intellectual disability
Federal law (Social Security Act Section 1862) prohibits Medicare from covering drugs used for weight loss
Is this normal?Community AnswerI do the same, so it can't be that abnormal
UHC often only covers Wegovy if the patient: Is requesting treatment for weight loss or appetite suppression Will also implement a lifestyle modification, like dietary restrictions, exercise, behavioral support, or other community programs Has a body mass index (BMI) at or above 30 kg/m for adults or in the 95th percentile for pediatric patients